Epidemiology and economics of statin use.
In 2006 the State supported the purchase of statins by some Euro 120 million for some 466,366 patients. While about 50% is for secondary prevention of heart disease a disproportionate number of women are receiving treatment for primary prevention. For proprietary agents the monthly cost was largely explained by price and dosage (mg/day) and the average varied from Euro 29.2 for rosuvastatin (11 mg), Euro 38.2 simvastatin (21 mg), Euro 39.1 atorvastatin (19 mg), Euro 42.7 pravastatin (21 mg) and Euro 31.8 for generic prava/simvastatin (21 mg). Generic substitution for pravastatin and simvastatin would save Euro 6.4m. Applying the drug prices corresponding in the United Kingdom would result in savings of some Euro 35m per annum. While the increasing use of statins is justified on cost benefit/analysis considerable savings could be made through choice of the more potent statins, a greater use of generics and a flatter dose price structure.